CME vs MA vs V Stock Comparison

Cme, Mastercard and Visa Prices as of Oct 26, 2026 Peers: Industry group
CME Cme Group Inc.
$308.06 +16.5% 1M +14.3% 1Y
Market cap
$110.11B
P/E
25.0x
Revenue (TTM)
$6.97B
Div. yield
3.25%
Exchanges Financial Services
6 wins
MA Mastercard Inc
$613.59 +8.1% 1M +7.0% 1Y
Market cap
$534.25B
P/E
33.3x
Revenue (TTM)
$35.08B
Div. yield
0.57%
Payment Networks Financial Services
2 wins
V Visa Inc.
$404.22 +10.1% 1M +16.4% 1Y
Market cap
$720.72B
P/E
29.9x
Revenue (TTM)
$44.49B
Div. yield
0.66%
Payment Networks Financial Services
4 wins

Head to Head

12 decided of 12

Cme leads on 6 of the 12 questions below (Cme 6, Visa 4, Mastercard 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCMEMAVLeader
Larger companyMarket capitalisation $110.11B $534.25B $720.72B V
Cheaper on earningsLower P/E, profitable companies only 25.0x 33.3x 29.9x CME
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.4x 29.2x 29.2x CME
Faster revenue growthRevenue growth, trailing twelve months +9.0% +16.0% +14.4% MA
More profitableNet margin, trailing twelve months 63.3% 46.3% 50.8% CME
Better return on capitalReturn on invested capital 11.7% 59.0% 38.1% MA
Less leveragedLower net debt / EBITDA 0.2x 0.6x 0.4x CME
Higher dividend yieldTrailing dividend yield 3.25% 0.57% 0.66% CME
Better 1-year returnPrice return, last 12 months +14.3% +7.0% +16.4% V
Better 5-year returnAnnualised price return, 5 years +7.3%/yr +12.8%/yr +13.4%/yr V
Less volatileAnnualised volatility, 1 year 25.0% 22.7% 22.2% V
Higher overall scoreMean of the five percentile scores vs peers 71/100 58/100 58/100 CME

Percentile Scorecard

CMEMAV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCMEMAV
Valuation 67 #22 of 64 33 #275 of 412 33 #278 of 412
Growth 50 #19 of 37 68 #98 of 301 54 #138 of 301
Profitability 94 #3 of 37 99 #5 of 317 97 #10 of 317
Financial Health 56 #32 of 72 57 #171 of 400 72 #113 of 400
Shareholder Returns 86 #2 of 8 31 #156 of 227 32 #154 of 227
Overall 71 58 58
  • CME ranked among 78 companies in Capital Markets
  • MA ranked among 469 companies in Financial Services
  • V ranked among 469 companies in Financial Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCMEMAVSPY
1 month +16.5%+8.1%+10.1% -0.8%
3 months +20.6%+11.2%+11.6% +3.5%
6 months +9.3%+21.2%+30.5% +7.0%
Year to date +12.8%+7.5%+15.3% +12.2%
1 year +14.3%+7.0%+16.4% +13.0%
3 years +47.4%+68.5%+76.3% +86.3%
3 years, per year +13.8%+19.0%+20.8% +23.1%
5 years +41.9%+82.8%+87.3% +68.6%
5 years, per year +7.3%+12.8%+13.4% +11.0%
10 years +199.6%+494.4%+394.5% +258.0%
10 years, per year +11.6%+19.5%+17.3% +13.6%

Risk

MeasureCMEMAVSPY
Volatility, 1Y 25.0%22.7%22.2% 12.7%
Downside volatility, 1Y 26.8%22.6%20.0% 12.7%
Beta vs S&P 500, 1Y -0.360.260.28 1.00
Return / volatility, 1Y 0.570.310.74 1.02
Max drawdown, 5Y -33.1%-28.6%-24.5% -25.4%
From 52-week high -5.6%-3.0%-2.4% -1.8%
52-week high $326.46$632.81$414.26 $779.14
52-week low $218.58$471.55$295.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCMEMAV
P/E now vs peer median 25.0xmedian 44.3x 33.3xmedian 19.9x 29.9xmedian 19.9x
P/S now vs peer median 15.8xmedian 4.1x 15.2xmedian 3.3x 16.2xmedian 3.3x
EV/EBITDA now vs peer median 22.9xmedian 10.0x 22.7xmedian 6.6x 25.8xmedian 6.6x
P/FCF now vs peer median 25.4xmedian 14.1x 32.0xmedian 11.8x 34.3xmedian 11.8x
P/B now vs peer median 4.1xmedian 1.5x 95.2xmedian 1.2x 20.5xmedian 1.2x
PEG now vs peer median 1.82median 0.50 1.70median 0.88 2.08median 0.88

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCMEMAV
Revenue $6.97B $35.08B $44.49B
Operating income $4.58B $20.47B $27.00B
Net income $4.42B $16.26B $22.59B
Free cash flow $4.33B $16.70B $21.01B
EPS (diluted) $12.31 $18.41 $11.90
Cash & equivalents $2.20B $11.29B $12.36B
Total debt $13.69B $81.59B $23.86B
Shares (diluted) 358.64M 883.00M 1.90B
Enterprise value $98.45B $494.17B $664.04B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCMEMAV
P/E 25.0x 33.3x 29.9x
P/FCF 25.4x 32.0x 34.3x
P/Operating cash flow 24.9x 30.6x 31.9x
P/S 15.8x 15.2x 16.2x
P/B 4.1x 95.2x 20.5x
P/Tangible book 4.6x 3,685x 94.3x
EV/EBITDA 22.9x 22.7x 25.8x
EV/EBIT 24.3x 26.8x 27.1x
EV/Revenue 15.9x 15.6x 16.5x
EV/FCF 25.7x 32.8x 34.8x
EV/Operating cash flow 25.1x 31.4x 32.4x
PEG (3Y EPS CAGR) 1.82 1.70 2.08

Growth

14 metrics
MetricCMEMAV
Revenue growth (1Y) 9.0% 16.0% 14.4%
Revenue CAGR (3Y) 9.2% 14.1% 11.8%
Gross profit growth (1Y) – – –
Gross profit CAGR (3Y) – – –
Operating income growth (1Y) 10.1% 21.3% 11.6%
Operating income CAGR (3Y) 12.2% 16.1% 9.5%
Net income growth (1Y) 17.3% 19.7% 11.4%
Net income CAGR (3Y) 13.1% 16.7% 11.0%
EPS growth (1Y) 19.4% 23.2% 14.9%
EPS CAGR (3Y) 13.7% 19.5% 14.4%
Operating cash flow growth (1Y) 6.4% 2.9% -3.9%
Operating cash flow CAGR (3Y) 9.3% 14.6% 4.6%
Free cash flow growth (1Y) 6.1% 0.9% -4.8%
Free cash flow CAGR (3Y) 9.4% 14.4% 4.0%

Profitability

14 metrics
MetricCMEMAV
Gross margin – – –
EBITDA margin 69.8% 68.6% 63.7%
Operating margin 65.7% 58.3% 60.7%
Pretax margin 82.8% 57.5% 60.6%
Net margin 63.3% 46.3% 50.8%
FCF margin 62.1% 47.6% 47.2%
Operating cash flow margin 63.5% 49.7% 50.8%
Return on equity 16.6% 263.6% 63.8%
Return on assets 2.3% 29.5% 23.8%
Return on invested capital 11.7% 59.0% 38.1%
Return on capital employed 12.3% 68.1% 42.6%
Asset turnover 0.0x 0.6x 0.5x
Cash conversion (OCF / net income) 1.0x 1.1x 1.0x
Stock comp / revenue 1.4% 1.8% 2.1%

Financial Health

11 metrics
MetricCMEMAV
Debt / assets 1.8% 42.7% 25.2%
Debt / equity 0.1x 4.4x 0.7x
Net debt / EBITDA 0.2x 0.6x 0.4x
Debt / FCF 0.8x 1.5x 1.1x
Liabilities / assets 86.2% 90.3% 62.8%
Equity / assets 13.8% 9.7% 37.2%
Interest coverage 26.2x 27.4x 34.8x
Current ratio 1.0x 1.1x 1.0x
Quick ratio 0.0x 0.7x 0.6x
Cash ratio 0.0x 0.5x 0.4x
Altman Z-score 0.58 10.19 8.87

Shareholder Returns

7 metrics
MetricCMEMAV
Dividend yield 3.2% 0.6% 0.7%
Net buyback yield – 2.9% 2.9%
Shareholder yield 3.2% 3.5% 3.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCMEMAV
Forward P/E 26.4xFY2026 29.2xFY2026 29.2xFY2026
EPS, next fiscal year $11.68FY2026 $20.99FY2026 $13.83FY2026
EPS growth, next FY +4.3%FY2026 +23.4%FY2026 +20.6%FY2026
EPS growth, the year after +18.1% +14.7% +11.6%
Revenue, next fiscal year $7.24BFY2026 $38.98BFY2026 $44.21BFY2026
Revenue growth, next FY +11.1%FY2026 +18.9%FY2026 +10.5%FY2026
Revenue growth, the year after +6.3% +0.4% +8.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCMEMAV
Held by institutions 88.9% 88.6% 87.6%
Institutions holding 1,691 3,581 4,526
Change in shares held, QoQ +0.4% +0.6% +2.4%
Institutions buying 822 1,587 2,327
Institutions selling 655 1,526 1,732
Buyers to sellers 1.25 1.04 1.34

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CMEMAV
CME 1.00 0.18 0.19
MA 0.18 1.00 0.87
V 0.19 0.87 1.00

Add a Peer

Largest companies in the same industry
CME · Exchanges

Related Comparisons

Frequently Asked Questions

Which is bigger, CME, MA and V?

Visa (V) is the largest by market capitalisation: Cme (CME) $110.11B, Mastercard (MA) $534.25B, Visa (V) $720.72B.

Which stock is cheaper, CME, MA and V?

Cme (CME) trades on the lowest price-to-earnings ratio (Cme (CME) 25.0x, Mastercard (MA) 33.3x, Visa (V) 29.9x). On next year's consensus earnings, Cme (CME) is cheapest (Cme (CME) 26.4x, Mastercard (MA) 29.2x, Visa (V) 29.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Mastercard (MA) grew revenue fastest over the trailing twelve months: Cme (CME) +9.0%, Mastercard (MA) +16.0%, Visa (V) +14.4%.

Which company is more profitable?

Cme (CME) has the highest net margin (Cme (CME) 63.3%, Mastercard (MA) 46.3%, Visa (V) 50.8%). On return on invested capital, Mastercard (MA) leads (Cme (CME) 11.7%, Mastercard (MA) 59.0%, Visa (V) 38.1%).

Which stock has performed better?

Over the past year Visa (V) returned the most: Cme (CME) +14.3%, Mastercard (MA) +7.0%, Visa (V) +16.4%. Over five years, Visa (V) compounded fastest (Cme (CME) +7.3%/yr, Mastercard (MA) +12.8%/yr, Visa (V) +13.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Cme (CME) has the highest dividend yield: Cme (CME) 3.25%, Mastercard (MA) 0.57%, Visa (V) 0.66%.

Which stock is riskier?

By one-year price volatility, Visa (V) has been the steadiest (Cme (CME) 25.0%, Mastercard (MA) 22.7%, Visa (V) 22.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CME, MA and V?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cme (CME) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.